Masayasu Kurono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Abstract: For increasing gene entrapping efficiency, it is preferable that liposome membrane to be formed is positively charged. For this purpose, a lipid with quaternary amine has been employed as one of constitutional lipids, but the such lipid may show toxicity to cells to be transformed with the gene for expression. The invention selects, as constitutional lipids for liposomes, N-(.alpha.-trimethylammonioacetyl)-didodecyl-D-glutamate chloride (TMAG), dilauroylphosphatidylcholine (DLPC), and dioleoylphosphatidylethanolamine (DOPE) with molar ratio of 1:2:2, and vortex treatment for preparing the liposomes with multi-layers to entrap the gene therein.
Abstract: There is disclosed a compound shown by a formula of ##STR1## wherein R.sub.1 is a hydrogen atom alkyl group having 1-4 carbon atoms or acyl group having 1-4 carbon atoms: R.sub.2 and R.sub.3 are a hydrogen atom, alkyl group having 1-4 carbon atoms, phenyl radical, halogen atom, cyano radical, acyl group having 1-4 carbon atoms, nitro radical, alkoxy group having 1 or 2 carbon atoms, or substituted or non-substituted amino group, respectively; n is an integer of 1-3; and dotted line means a possible ring, and a salt thereof. The compound and salt bind with muscarinic receptor in brain to develop a powerful actuation thereof and thus those can be used as an effective ingredient for preventing and curing senile dementias, and more particularly Alzheimer's disease.
Abstract: A method of enzymatically measuring hydrogen peroxide by developing a color with use of 3-methyl-2-benzothiazolinoehydrazone as a coupler and in combination with an oxidative color developing reagent with peroxidase, and a reagent therefor is described. Catalase is added to the 3-methyl-2-benzothiazolinonehydrazone reagent as a stabilizer and the reaction is carried out in the presence of ethylenediaminetetraacetic acid or an analogue thereof. The color developing reaction may be carried out in neutral or weak alkali conditions. A reagent is described which comprises a buffer, 3-methyl-2-benzothiazolinohydrazone, and catalase.
Abstract: A readily absorbable type of motilin preparation containing a motilin-like active substance and a surface active agent is provided, in which the motilin-like active substance is mainly L-leucine-13-motilin-homoserine, and the surface active agent is selected from the group consisting of a bile salt, saponin and a polyethylene glycol higher-alcohol ether for nasal administration purposes and is a peptide lytic enzyme inhibitor for oral administration purposes.
Abstract: A process for the preparation of a polypeptide of the formula ##STR1## wherein A' is Pro, Gly, Asp or Ser; B' is Gly, Asn or Ser; C is Gln, Glu or Asp; D is Asn, Glu or Asp; X' is a residue of amino acid other than Met; E is Gln, Lys or Arg, and Y' is a residue of homoserine or homoserine-lactone, as well as a recombinant DNA and expression plasmid for preparing the polypeptide.
Abstract: Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom,--CH.sub.2 OH.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.
Abstract: An aromatic amino-substituted compound represented by formula: ##STR1## wherein A represents CH, N, or N.fwdarw.O; R.sub.1 represents a nitro group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, or an acyl group; and R.sub.3 represents a group: ##STR2## wherein m represents 0 or 1; n represents an integer of from 0 to 3; R.sub.4 and R.sub.5 each represents a hydrogen atom or a lower alkyl group; R.sub.6 and R.sub.7 each represents a hydrogen atom or a straight chain or branched lower alkyl group; R.sub.4 and R.sub.6 may be joined together to form an alkylene chain forming a heterocyclic ring; R.sub.5 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring and R.sub.6 and R.sub.
Abstract: Early diagnosis of mastitis or garget is carried out by measuring the concentration of 3-hydroxybutyric acid in milk. Used to this end is a reagent reacting with 3-hydroxybutyric acid to show a color at a concentration of 100 .mu.mol/l or higher.
Abstract: A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.
Abstract: Vasoactive intestinal polypeptide (VIP) analogues and use thereof are disclosed. The VIP analogues are shown by the formula ofHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-X-Ala-Val-L ys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Ywherein X is a residue of amino acid other than methionine (Met); and Y is homoserine, homoserine-lactone, amidized homoserine, a residue reacted homoserine-lactone with a primary alkyl amine having carbon atoms not exceeding 20, or an optional polypeptide chain and containing an amidized homoserine at C-terminal.Each of the VIP analogues is employed as an effective ingredient for various medicines and a hair tonic, and more particularly curing an asthma and impotence.
Abstract: There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.
Abstract: A process for separating and recovering serum and plasma components from a whole blood sample including passing a whole blood sample through a separating filter formed of a blood cell separating layer composed mainly of fibers impregnated with a coating agent. A device includes a blood collector having a needle at one end and a blood suction means at the other end, and a separating filter including a blood cell separating layer, the filter being provided in the intermediate zone of the blood collector, whereby a whole blood sample sucked through the needle by depressurizing the blood suction means is passed through the separating filter.
Abstract: The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.
Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition. The treatment of hepatitis with compositions containing this germanium derivative.
Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition.
Abstract: There is disclosed a pharmaceutical composition of stabilized [Leu.sup.13 ]-motilin-Hse. The composition comprises at least one of organic acids and salts thereof, as a first stabilizer, and pH thereof is adjusted in a range of 5.5-8.0. The composition may contain at least one of substances selected from saccharides, amino acids, proteins and salts thereof, as a second stabilizer. Conversion of [Leu.sup.13 ]-motilin-Hse into [Leu.sup.13 ]-motilin-Hse-lactone is suppressed by increasing pH value and deamidization in asparagine residue at 19-position is suppressed by the presence of the organic acid or salt thereof.
Abstract: Even when the specimen contains human granulocyte elastase in the form of a mixture of free elastase with an elastase-inhibitor complex or complexes, the present invention enables the total quantity of elastase in that specimen to be precisely detected. The inhibitor is added to free elastase to convert it into an elastase-inhibitor complex, whereby the quantity of elastase can be measured by immunoassay as the total amount including the previously existing elastase-inhibitor complex. It is possible to precisely measure the total amount of elastase in mucus collected from the cervical canal of a pregnant woman, sputum or a rinsed solution of bronchovesicular lavage in which free elastase is mixed with an elastase-inhibitor complex.
Abstract: A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.
Abstract: An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.